Literature DB >> 7550348

Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration.

M A Kay1, A X Holterman, L Meuse, A Gown, H D Ochs, P S Linsley, C B Wilson.   

Abstract

Recombinant adenovirus vectors are efficient at transferring genes into somatic tissues but are limited for use in clinical gene therapy by immunologic factors that result in the rapid loss of gene expression and inhibit secondary gene transfer. This study demonstrates that systemic coadministration of recombinant adenovirus with soluble CTLA4Ig, which is known to block co-stimulatory signals between T cells and antigen presenting cells, leads to persistent adenoviral gene expression in mice without long-term immunosuppression. This form of immunotherapy greatly enhances the likelihood that recombinant adenovirus vectors will be useful for human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550348     DOI: 10.1038/ng1095-191

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  45 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 2.  Gene therapy for the hemophilias.

Authors:  M A Kay; K High
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

Authors:  K B Elkon; C C Liu; J G Gall; J Trevejo; M W Marino; K A Abrahamsen; X Song; J L Zhou; L J Old; R G Crystal; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 6.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

7.  The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.

Authors:  A Lieber; C Y He; L Meuse; D Schowalter; I Kirillova; B Winther; M A Kay
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

8.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

9.  Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver.

Authors:  J T Bruder; T Jie; D L McVey; I Kovesdi
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 10.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.